These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

362 related articles for article (PubMed ID: 15667232)

  • 41. Psoriatic nail disease: quality of life and treatment.
    Gupta AK; Cooper EA
    J Cutan Med Surg; 2009; 13 Suppl 2():S102-6. PubMed ID: 19799826
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Progressive multifocal leukoencephalopathy associated with efalizumab use in psoriasis patients.
    Kothary N; Diak IL; Brinker A; Bezabeh S; Avigan M; Dal Pan G
    J Am Acad Dermatol; 2011 Sep; 65(3):546-551. PubMed ID: 21514689
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Biologic therapy for psoriasis--the first wave: infliximab, etanercept, efalizumab, and alefacept.
    Weinberg JM; Saini R; Tutrone WD
    J Drugs Dermatol; 2002 Dec; 1(3):303-10. PubMed ID: 12851990
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Long-term efficacy of biologics in the treatment of psoriasis: what do we really know?
    Alwawi EA; Krulig E; Gordon KB
    Dermatol Ther; 2009; 22(5):431-40. PubMed ID: 19845720
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Economic evaluation of biologic therapies for the treatment of moderate to severe psoriasis in the United States.
    Anis AH; Bansback N; Sizto S; Gupta SR; Willian MK; Feldman SR
    J Dermatolog Treat; 2011 Apr; 22(2):65-74. PubMed ID: 20443663
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Comparative effects of biological therapies on the severity of skin symptoms and health-related quality of life in patients with plaque-type psoriasis: a meta-analysis.
    Reich K; Sinclair R; Roberts G; Griffiths CE; Tabberer M; Barker J
    Curr Med Res Opin; 2008 May; 24(5):1237-54. PubMed ID: 18355421
    [TBL] [Abstract][Full Text] [Related]  

  • 48. TNF-α in a molecularly targeted therapy of psoriasis and psoriatic arthritis.
    Wcisło-Dziadecka D; Zbiciak-Nylec M; Brzezińska-Wcisło L; Mazurek U
    Postgrad Med J; 2016 Mar; 92(1085):172-8. PubMed ID: 26719452
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Impact of a Patient Support Program on Patient Adherence to Adalimumab and Direct Medical Costs in Crohn's Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Psoriatic Arthritis, and Ankylosing Spondylitis.
    Rubin DT; Mittal M; Davis M; Johnson S; Chao J; Skup M
    J Manag Care Spec Pharm; 2017 Aug; 23(8):859-867. PubMed ID: 28737994
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Infliximab in psoriasis and psoriatic arthritis.
    Papoutsaki M; Osório F; Morais P; Torres T; Magina S; Chimenti S; Costanzo A
    BioDrugs; 2013 Jan; 27 Suppl 1():13-23. PubMed ID: 23990278
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Use of biologic therapeutics in difficult-to-treat psoriasis.
    Lynde C
    J Cutan Med Surg; 2009; 13(1):6-17. PubMed ID: 19298766
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Treatment of psoriatic arthritis and recalcitrant skin disease with combination therapy.
    Hamilton TK
    J Drugs Dermatol; 2008 Nov; 7(11):1089-93. PubMed ID: 19110745
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Integrating biologic agents into management of moderate-to-severe psoriasis: a consensus of the Canadian Psoriasis Expert Panel. February 27, 2004.
    Guenther L; Langley RG; Shear NH; Bissonnette R; Ho V; Lynde C; Murray E; Papp K; Poulin Y; Zip C
    J Cutan Med Surg; 2004; 8(5):321-37. PubMed ID: 15868311
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Application of economic analyses in U.S. managed care formulary decisions: a private payer's experience.
    Watkins JB; Minshall ME; Sullivan SD
    J Manag Care Pharm; 2006; 12(9):726-35. PubMed ID: 17249905
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Alefacept: its safety profile, off-label uses, and potential as part of combination therapies for psoriasis.
    Scheinfeld N
    J Dermatolog Treat; 2007; 18(4):197-208. PubMed ID: 17671880
    [TBL] [Abstract][Full Text] [Related]  

  • 56. To test or not to test? An updated evidence-based assessment of the value of screening and monitoring tests when using systemic biologic agents to treat psoriasis and psoriatic arthritis.
    Ahn CS; Dothard EH; Garner ML; Feldman SR; Huang WW
    J Am Acad Dermatol; 2015 Sep; 73(3):420-8.e1. PubMed ID: 26184440
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Biologic therapies for psoriasis: practical experience in a U.K. tertiary referral centre.
    Warren RB; Brown BC; Lavery D; Ashcroft DM; Griffiths CE
    Br J Dermatol; 2009 Jan; 160(1):162-9. PubMed ID: 18808412
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Long-term safety of biologics in the treatment of moderate-to-severe plaque psoriasis: review of current data.
    Rustin MH
    Br J Dermatol; 2012 Nov; 167 Suppl 3():3-11. PubMed ID: 23082810
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Fulfilling an unmet need in psoriasis : do biologicals hold the key to improved tolerability?
    Shear NH
    Drug Saf; 2006; 29(1):49-66. PubMed ID: 16454534
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Review of eight pharmacoeconomic studies of the value of biologic DMARDs (adalimumab, etanercept, and infliximab) in the management of rheumatoid arthritis.
    Doan QV; Chiou CF; Dubois RW
    J Manag Care Pharm; 2006 Sep; 12(7):555-69. PubMed ID: 16981801
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.